SI3505174T1 - Deoksinukleozidna terapija za bolezni, ki jih povzročajo neuravnotežene nukleotidne zbirke, vključno s sindromi deplecije mitohondrijske dnk - Google Patents

Deoksinukleozidna terapija za bolezni, ki jih povzročajo neuravnotežene nukleotidne zbirke, vključno s sindromi deplecije mitohondrijske dnk

Info

Publication number
SI3505174T1
SI3505174T1 SI201630830T SI201630830T SI3505174T1 SI 3505174 T1 SI3505174 T1 SI 3505174T1 SI 201630830 T SI201630830 T SI 201630830T SI 201630830 T SI201630830 T SI 201630830T SI 3505174 T1 SI3505174 T1 SI 3505174T1
Authority
SI
Slovenia
Prior art keywords
diseases caused
mitochondrial dna
dna depletion
including mitochondrial
nucleotide pools
Prior art date
Application number
SI201630830T
Other languages
English (en)
Slovenian (sl)
Inventor
Michio Hirano
Caterina Garone
Ramon Marti
Original Assignee
The Trustees Of Columbia University In The City Of New York,
Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Trustees Of Columbia University In The City Of New York,, Fundacio Hospital Universitari Vall D'hebron - Institut De Recerca filed Critical The Trustees Of Columbia University In The City Of New York,
Publication of SI3505174T1 publication Critical patent/SI3505174T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
SI201630830T 2015-06-17 2016-06-17 Deoksinukleozidna terapija za bolezni, ki jih povzročajo neuravnotežene nukleotidne zbirke, vključno s sindromi deplecije mitohondrijske dnk SI3505174T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562180914P 2015-06-17 2015-06-17
EP19156021.8A EP3505174B1 (en) 2015-06-17 2016-06-17 Deoxynucleoside therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes

Publications (1)

Publication Number Publication Date
SI3505174T1 true SI3505174T1 (sl) 2021-02-26

Family

ID=57546446

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201630830T SI3505174T1 (sl) 2015-06-17 2016-06-17 Deoksinukleozidna terapija za bolezni, ki jih povzročajo neuravnotežene nukleotidne zbirke, vključno s sindromi deplecije mitohondrijske dnk
SI201630439T SI3310362T1 (sl) 2015-06-17 2016-06-17 Deoksinukleozidna terapija za bolezni, povzročene z neuravnoteženimi nabori nukleotidov, vključno s sindromom pomanjkanja mitohondrijske DNA

Family Applications After (1)

Application Number Title Priority Date Filing Date
SI201630439T SI3310362T1 (sl) 2015-06-17 2016-06-17 Deoksinukleozidna terapija za bolezni, povzročene z neuravnoteženimi nabori nukleotidov, vključno s sindromom pomanjkanja mitohondrijske DNA

Country Status (24)

Country Link
US (5) US10471087B2 (enExample)
EP (3) EP3569236A1 (enExample)
JP (3) JP6599484B2 (enExample)
KR (3) KR20220018623A (enExample)
CN (2) CN116726035A (enExample)
AU (3) AU2016280293B2 (enExample)
BR (2) BR112017027079B1 (enExample)
CA (1) CA2989653A1 (enExample)
CY (2) CY1122605T1 (enExample)
DK (2) DK3310362T3 (enExample)
ES (2) ES2748556T3 (enExample)
HK (1) HK1252133A1 (enExample)
HR (2) HRP20191794T1 (enExample)
HU (2) HUE046399T2 (enExample)
IL (3) IL275256B2 (enExample)
LT (2) LT3505174T (enExample)
MX (2) MX389016B (enExample)
PL (2) PL3310362T3 (enExample)
PT (2) PT3310362T (enExample)
RS (2) RS59724B1 (enExample)
RU (1) RU2721492C2 (enExample)
SI (2) SI3505174T1 (enExample)
SM (2) SMT201900571T1 (enExample)
WO (1) WO2016205671A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9549909B2 (en) 2013-05-03 2017-01-24 The Katholieke Universiteit Leuven Method for the treatment of dravet syndrome
US10292996B2 (en) * 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
PL3310362T3 (pl) * 2015-06-17 2020-04-30 The Trustees Of Columbia University In The City Of New York Terapia deoksynukleozydowa chorób spowodowanych przez niezrównoważoną pulę nukleotydów włączając zespół deplecji mitochondrialnego DNA
FI3800177T3 (fi) 2015-12-22 2025-04-29 Zogenix International Ltd Fenfluramiinikoostumukset ja menetelmät niiden valmistamiseksi
US20170174614A1 (en) 2015-12-22 2017-06-22 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
EP4201427A1 (en) 2016-08-24 2023-06-28 Zogenix International Limited Formulation for inhibiting formation of 5-ht 2b agonists and methods of using same
WO2019051097A1 (en) 2017-09-08 2019-03-14 The Regents Of The University Of California RNA-GUIDED ENDONUCLEASE FUSION POLYPEPTIDES AND METHODS OF USING SAME
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
WO2019200340A1 (en) * 2018-04-12 2019-10-17 Modis Therapeutics Inc. Prodrugs of deoxynucleosides for treatment of diseases cased by unbalanced nucleotide pools
CN112312929A (zh) 2018-04-18 2021-02-02 纽约市哥伦比亚大学理事会 用于包括线粒体dna耗竭综合征在内的由不平衡的核苷酸库引起的疾病的基因疗法
US11571397B2 (en) 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
CA3117868A1 (en) 2018-11-19 2020-05-28 Zogenix International Limited Methods of treating rett syndrome using fenfluramine
CA3150755A1 (en) * 2019-08-19 2021-02-25 Modis Therapeutics, Inc. Polymorphic forms of deoxycytidine, compositions comprising the same and uses
IL322998A (en) * 2019-09-05 2025-10-01 Mitorainbow Therapeutics Inc Treatment of mitochondrial DNA depletion disorders
WO2021188840A1 (en) 2020-03-19 2021-09-23 Rewrite Therapeutics, Inc. Methods and compositions for directed genome editing
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US20220096514A1 (en) * 2020-09-29 2022-03-31 Zogenix International Limited Methods of treating thymidine kinase 2 deficiency by administering deoxycytidine and deoxythymidine
JPWO2022145439A1 (enExample) * 2020-12-28 2022-07-07
MX2023011053A (es) 2021-03-26 2023-10-16 Zogenix Inc Soluciones acuosas que contienen purinas y pirimidinas, y usos de las mismas.
IL309421A (en) * 2021-06-18 2024-02-01 Zogenix Inc Deoxynucleoside preparations for the treatment of mitochondrial diseases caused by unbalanced nucleotide pools
IL318214A (en) * 2022-07-12 2025-03-01 Ucb Biosciences Inc Methods for increasing the bioavailability of nucleoside medicinal substances
WO2024206595A2 (en) * 2023-03-30 2024-10-03 The Trustees Of Columbia University In The City Of New York Pharmacological therapy for mitochondrial dna depletion deletions syndrome involving mutations in the guk1 gene

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1911237B (zh) * 1998-08-10 2010-09-15 艾丹尼克斯(开曼)有限公司 用于治疗乙型肝炎的β-L-2＇-脱氧-核苷
EP1171137B1 (en) * 1999-02-23 2007-12-26 The Regents of the University of California Use of triacetyluridine for the treatment of mitochondrial disorders
DE60105424T2 (de) * 2000-05-26 2005-09-22 Idenix (Cayman) Ltd. Methoden zur behandlung von delta hepatitis virus infektionen mit beta-l-2' deoxy-nucleosiden
WO2012125848A2 (en) * 2011-03-16 2012-09-20 Baylor College Of Medicine A method for comprehensive sequence analysis using deep sequencing technology
US10292996B2 (en) 2015-03-26 2019-05-21 The Trustees Of Columbia University In The City Of New York Deoxyribonucleoside monophospate bypass therapy for mitochondrial DNA depletion syndrome
DK3302499T3 (da) * 2015-06-05 2023-04-03 Fundacio Hospital Univ Vall D Hebron Institut De Recerca Behandling af mitokondrielle sygdomme
PL3310362T3 (pl) * 2015-06-17 2020-04-30 The Trustees Of Columbia University In The City Of New York Terapia deoksynukleozydowa chorób spowodowanych przez niezrównoważoną pulę nukleotydów włączając zespół deplecji mitochondrialnego DNA

Also Published As

Publication number Publication date
US20230277577A1 (en) 2023-09-07
LT3310362T (lt) 2019-11-11
WO2016205671A9 (en) 2018-01-04
KR20180039624A (ko) 2018-04-18
EP3569236A1 (en) 2019-11-20
US20200038424A1 (en) 2020-02-06
PT3505174T (pt) 2020-07-06
US20210244754A1 (en) 2021-08-12
CA2989653A1 (en) 2016-12-22
RU2018101305A (ru) 2019-07-17
AU2016280293B2 (en) 2020-07-02
JP6675037B2 (ja) 2020-04-01
HRP20200949T1 (hr) 2020-10-02
AU2020204042B2 (en) 2021-07-15
BR112017027079B1 (pt) 2021-04-27
US12251392B2 (en) 2025-03-18
HRP20191794T1 (hr) 2020-02-07
SMT202000399T1 (it) 2020-09-10
IL275256B1 (en) 2023-05-01
HK1252133A1 (zh) 2019-05-17
MX2020000269A (es) 2022-01-03
SI3310362T1 (sl) 2020-02-28
JP2018521993A (ja) 2018-08-09
PL3310362T3 (pl) 2020-04-30
US20180133241A1 (en) 2018-05-17
AU2021250841A1 (en) 2021-11-04
PT3310362T (pt) 2019-10-29
MX389016B (es) 2025-03-20
EP3505174B1 (en) 2020-04-29
US11666592B2 (en) 2023-06-06
EP3310362B1 (en) 2019-08-28
EP3310362A1 (en) 2018-04-25
KR20220018623A (ko) 2022-02-15
EP3310362A4 (en) 2018-12-19
US11110111B2 (en) 2021-09-07
LT3505174T (lt) 2020-09-10
JP7036782B2 (ja) 2022-03-15
AU2020204042A1 (en) 2020-07-09
MX2017016425A (es) 2018-12-11
ES2808148T3 (es) 2021-02-25
IL275256B2 (en) 2023-09-01
BR122020021913B1 (pt) 2021-07-06
RU2020112901A (ru) 2020-06-05
CY1123107T1 (el) 2021-10-29
IL256331B (en) 2020-08-31
PL3505174T3 (pl) 2020-08-24
RS60572B1 (sr) 2020-08-31
IL275256A (en) 2020-07-30
CN116726035A (zh) 2023-09-12
JP6599484B2 (ja) 2019-10-30
AU2021250841B2 (en) 2023-02-09
CN107847512A (zh) 2018-03-27
KR20250048602A (ko) 2025-04-09
RU2018101305A3 (enExample) 2019-10-31
CY1122605T1 (el) 2021-03-12
SMT201900571T1 (it) 2019-11-13
WO2016205671A1 (en) 2016-12-22
RS59724B1 (sr) 2020-01-31
JP2020019792A (ja) 2020-02-06
HUE046399T2 (hu) 2020-03-30
US20250360154A1 (en) 2025-11-27
RU2721492C2 (ru) 2020-05-19
DK3310362T3 (da) 2019-10-07
AU2016280293A1 (en) 2018-02-08
ES2748556T3 (es) 2020-03-17
EP3505174A1 (en) 2019-07-03
US10471087B2 (en) 2019-11-12
DK3505174T3 (da) 2020-07-13
IL275255A (en) 2020-07-30
IL256331A (en) 2018-02-28
JP2020019791A (ja) 2020-02-06
IL275255B (en) 2021-04-29
HUE050678T2 (hu) 2020-12-28

Similar Documents

Publication Publication Date Title
IL275256A (en) Deoxynucleoside treatment for diseases caused by unbalanced stores of nucleotides including mitochondrial DNA depletion syndromes
IL256634A (en) Therapeutic oligonucleotides
DK3294323T3 (da) Adeno-associeret virus til terapeutisk indgivelse til centralnervesystemet
DK3171929T3 (da) Dosering til nervestimulation
IL254632A0 (en) RNA interference-mediated therapy for neurodegenerative diseases
DK3262066T4 (da) Genterapi
GB201412973D0 (en) Adjustable steering columns
EP3302248A4 (en) DOSAGE CONFIRMATION DEVICE
IL259864A (en) Monomaleimide-functionalized platinum compounds for cancer therapy
GB2524625B (en) Purification column
GB201521217D0 (en) Dosage regimens
DK3329004T3 (da) Terapeutiske oligonukleotider
SMT201900624T1 (it) Piantone di sterzo
PL3244860T3 (pl) Kolumna stołu operacyjnego
PL3261679T3 (pl) Terapia genowa dla poprawy wzroku
GB201512617D0 (en) Single-stranded DNA sensor
HK40045628A (en) Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial dna depletion syndromes
FI11038U1 (fi) Aitapylväs
GB201519323D0 (en) Nucleic acid analysis
GB201503845D0 (en) Nucleic acid analysis